These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31434557)

  • 1. The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review.
    Velissaris D; Pierrakos C; Karamouzos V; Pantzaris ND; Gogos C
    Acta Clin Belg; 2021 Feb; 76(1):79-84. PubMed ID: 31434557
    [No Abstract]   [Full Text] [Related]  

  • 2. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study.
    Uusitalo-Seppälä R; Huttunen R; Tarkka M; Aittoniemi J; Koskinen P; Leino A; Vahlberg T; Rintala EM
    J Intern Med; 2012 Sep; 272(3):247-56. PubMed ID: 22755554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.
    Ni W; Han Y; Zhao J; Cui J; Wang K; Wang R; Liu Y
    Sci Rep; 2016 Dec; 6():39481. PubMed ID: 27991579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
    Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
    Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis.
    Okulu E; Arsan S; Akin IM; Ates C; Alan S; Kilic A; Atasay B
    J Clin Lab Anal; 2015 Sep; 29(5):347-52. PubMed ID: 25043869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
    Chenevier-Gobeaux C; Lemarechal H; Doumenc B; Peschanski N; Claessens YE; Borderie D; Ray P
    Clin Biochem; 2021 Jun; 92():19-24. PubMed ID: 33662350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.
    Backes Y; van der Sluijs KF; Mackie DP; Tacke F; Koch A; Tenhunen JJ; Schultz MJ
    Intensive Care Med; 2012 Sep; 38(9):1418-28. PubMed ID: 22706919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.
    El-Mekkawy MS; Saleh NY; Sonbol AA
    Indian J Pediatr; 2016 Jul; 83(7):661-9. PubMed ID: 26960717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombo-inflammatory biomarkers to predict sepsis outcome.
    Efat A; Shoeib SA; Arafa AF; Dawod AA; Abd ElHafez MA; Abd ElMohsen EA; Eladly HF; Ibrahim RA; Elkholy A
    Int J Immunopathol Pharmacol; 2021; 35():20587384211048561. PubMed ID: 34647483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic power of soluble urokinase plasminogen activator receptor (suPAR) for short-term mortality in patients seen in Emergency Departments due to infections].
    Rubio Díaz R; de Rafael González E; Martín Torres E; Valera Núñez E; López Martos AM; Melguizo Melguizo D; Picazo Perea MP; López García PJ; Fuentes Bullejos P; Chafer Rudilla M; Carretero Gómez JF; Julián-Jiménez A
    Rev Esp Quimioter; 2022 Feb; 35(1):50-62. PubMed ID: 34859658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
    Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
    Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. suPAR as a prognostic biomarker in sepsis.
    Donadello K; Scolletta S; Covajes C; Vincent JL
    BMC Med; 2012 Jan; 10():2. PubMed ID: 22221662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.
    Zeng M; Chang M; Zheng H; Li B; Chen Y; He W; Huang C
    Am J Emerg Med; 2016 Mar; 34(3):375-80. PubMed ID: 26615223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Diagnostic and Prognostic Value of suPAR in Patients with Sepsis: A Systematic Review and Meta-Analysis.
    Huang Q; Xiong H; Yan P; Shuai T; Liu J; Zhu L; Lu J; Yang K; Liu J
    Shock; 2020 Apr; 53(4):416-425. PubMed ID: 31490358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis.
    Savva A; Raftogiannis M; Baziaka F; Routsi C; Antonopoulou A; Koutoukas P; Tsaganos T; Kotanidou A; Apostolidou E; Giamarellos-Bourboulis EJ; Dimopoulos G
    J Infect; 2011 Nov; 63(5):344-50. PubMed ID: 21839112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic value of soluble urokinase plasminogen activator receptor (suPAR) compared to C-reactive protein (CRP) and procalcitonin (PCT) in children with systemic inflammatory response syndrome (SIRS).
    Şirinoğlu M; Soysal A; Karaaslan A; Kepenekli Kadayifci E; Yalındağ-Öztürk N; Cinel İ; Yaman A; Haklar G; Şirikci Ö; Turan S; Altınkanat Gelmez G; Söyletir G; Bakır M
    J Infect Chemother; 2017 Jan; 23(1):17-22. PubMed ID: 27771157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
    Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
    J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase plasminogen activator receptor informs on the progression course after multiple injuries.
    Patrani M; Tsaganos T; Kotzampassi K; Paraschos M; Katsenos C; Giamarellos-Bourboulis EJ; Mandragos K
    Biomarkers; 2016 Nov; 21(7):660-4. PubMed ID: 27121128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis.
    Zhao JJ; Lou XL; Chen HW; Zhu FT; Hou YQ
    Cell Mol Biol Lett; 2018; 23():22. PubMed ID: 29760745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study.
    Nusshag C; Rupp C; Schmitt F; Krautkrämer E; Speer C; Kälble F; Tamulyte S; Bruckner T; Zeier M; Reiser J; Weigand MA; Uhle F; Merle U; Morath C; Brenner T
    Crit Care Med; 2019 Dec; 47(12):e999-e1007. PubMed ID: 31584458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.